Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) have earned an average rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $13.70.
VNDA has been the topic of a number of recent analyst reports. B. Riley Financial restated a "buy" rating and issued a $12.00 target price (down from $17.00) on shares of Vanda Pharmaceuticals in a research note on Monday, August 10th. HC Wainwright decreased their price target on Vanda Pharmaceuticals from $21.00 to $20.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a report on Friday, July 17th.
Get Our Latest Analysis on Vanda Pharmaceuticals
Institutional Investors Weigh In On Vanda Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP bought a new position in Vanda Pharmaceuticals during the second quarter worth $29,000. Russell Investments Group Ltd. boosted its holdings in Vanda Pharmaceuticals by 456.6% in the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 5,328 shares during the period. Legal & General Group Plc bought a new stake in Vanda Pharmaceuticals during the second quarter valued at $34,000. Allworth Financial LP bought a new stake in Vanda Pharmaceuticals during the second quarter valued at $43,000. Finally, Quarry LP acquired a new stake in shares of Vanda Pharmaceuticals during the third quarter worth $53,000. 88.14% of the stock is currently owned by institutional investors.
Vanda Pharmaceuticals Stock Performance
Shares of VNDA opened at $5.43 on Monday. The firm has a market cap of $328.30 million, a price-to-earnings ratio of -1.17 and a beta of 0.64. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01. The business's 50 day moving average is $5.51 and its two-hundred day moving average is $6.44. Vanda Pharmaceuticals has a 52-week low of $4.27 and a 52-week high of $9.94.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.46). The company had revenue of $50.53 million during the quarter, compared to the consensus estimate of $61.92 million. Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%. Analysts forecast that Vanda Pharmaceuticals will post -3 EPS for the current fiscal year.
About Vanda Pharmaceuticals
(
Get Free Report)
Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company's research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda's mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.
Vanda's flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
